HCW Biologics Inc. (HCWB) Financial Statements (2024 and earlier)

Company Profile

Business Address 2929 N COMMERCE PKWY
MIRAMAR, FL 33025
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments32,06236,714
Cash and cash equivalents22,32611,731
Short-term investments 9,73624,984
Receivables418133
Prepaid expense1,3952,197
Other current assets1961,437
Total current assets:34,07140,480
Noncurrent Assets
Operating lease, right-of-use asset  
Property, plant and equipment10,8051,119
Long-term investments and receivables1,60011,522
Long-term investments1,60011,522
Other noncurrent assets334393
Other undisclosed noncurrent assets  
Total noncurrent assets:12,73813,034
TOTAL ASSETS:46,80953,515
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,7002,100
Accounts payable1,226224
Other undisclosed accounts payable and accrued liabilities4741,876
Deferred revenue 1,800 
Debt38,273 
Other undisclosed current liabilities(38,817)222
Total current liabilities:2,9562,322
Noncurrent Liabilities
Liabilities, other than long-term debt 14 
Operating lease, liability 14 
Other undisclosed noncurrent liabilities6,410 
Total noncurrent liabilities:6,424 
Total liabilities:9,3812,322
Equity
Equity, attributable to parent, including:37,42951,193
Common stock4 
Additional paid in capital82,96381,827
Accumulated deficit(45,538)(30,637)
Other undisclosed equity, attributable to parent  4
Total equity:37,42951,193
TOTAL LIABILITIES AND EQUITY:46,80953,515

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
Revenues6,722 
Cost of revenue(4,136) 
Gross profit:2,586 
Operating expenses(17,665)(13,368)
Operating loss:(15,079)(13,368)
Interest and debt expense(127)567
Other undisclosed loss from continuing operations before equity method investments, income taxes  
Loss from continuing operations before equity method investments, income taxes:(15,205)(12,801)
Other undisclosed income (loss) from continuing operations before income taxes305(62)
Loss from continuing operations:(14,901)(12,862)
Loss before gain (loss) on sale of properties:(12,862)
Net loss:(14,901)(12,862)
Other undisclosed net income attributable to parent  
Net loss available to common stockholders, diluted:(14,901)(12,862)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
Net loss:(14,901)(12,862)
Comprehensive loss, net of tax, attributable to parent:(14,901)(12,862)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: